-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 15, NMPA's official website showed that Jiangsu Hengrui Medicine's medium and long-chain fatty emulsion/amino acid (16)/glucose (16%) injection was approved (Guoyao Zhunzi H20223219); on the same day, the company announced that gadolinium The abbreviated new drug application (ANDA) for meglumine acid injection has been approved
.
.
Figure 1: Sales of medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection is an "all-in-one" parenteral nutrition injection, used for mild to moderate when oral or enteral nutrition cannot be performed, insufficient or contraindicated.
Patients with severe catabolism provide energy, essential fatty acids, amino acids, electrolytes, and fluids for parenteral nutrition therapy
.
Patients with severe catabolism provide energy, essential fatty acids, amino acids, electrolytes, and fluids for parenteral nutrition therapy
.
At present, in addition to the original research and imported drugs in the domestic market, Kelun and Hisco obtained the production approval in 2018, and subsequently passed the consistency evaluation.
This product is the third domestic enterprise
.
This product is the third domestic enterprise
.
According to data from Minet.
com, domestic brands have boosted the sales of products after their listing.
In 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, medium and long-chain fat emulsion / The sales growth rate of amino acid (16)/glucose (16%) injection is as high as 238.
64%, and there is also a 172% increase in the first half of 2021
.
From the perspective of the corporate structure, domestic brands have jointly grabbed the market leadership, and the market share of original research pharmaceutical companies will be less than 1% in the first half of 2021
.
com, domestic brands have boosted the sales of products after their listing.
In 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, medium and long-chain fat emulsion / The sales growth rate of amino acid (16)/glucose (16%) injection is as high as 238.
64%, and there is also a 172% increase in the first half of 2021
.
From the perspective of the corporate structure, domestic brands have jointly grabbed the market leadership, and the market share of original research pharmaceutical companies will be less than 1% in the first half of 2021
.
Table 1: The ANDA number that Hengrui has obtained
Source: Minet Global Listed Drug Database
On April 15, Jiangsu Hengrui Pharmaceutical announced that the company's abbreviated new drug application (ANDA) for gadoteric acid meglumine injection submitted to the US FDA was approved, which means that the product can be produced and sold in the US market
.
.
It is reported that gadoteric acid meglumine injection is a gadolinium-based intravenous contrast agent for MRI of the brain (intracranial), spine and related tissues in adults and children (including neonates) to check for blood-brain barrier damage and Vascular abnormalities
.
In the first half of 2021, Hengrui's gadoteric acid meglumine injection ranked twelfth among the TOP20 brands of terminal contrast media in China's public medical institutions
.
.
In the first half of 2021, Hengrui's gadoteric acid meglumine injection ranked twelfth among the TOP20 brands of terminal contrast media in China's public medical institutions
.
In recent years, Hengrui has been actively deploying preparations to go overseas.
So far, nearly 20 ANDA approvals have been obtained, most of which are injections
.
So far, nearly 20 ANDA approvals have been obtained, most of which are injections
.
Source: NMPA official website, Minet database
Note: The statistics of the global marketed drug database of Minet.
com are as of April 6.
If there are any omissions, please correct me!
com are as of April 6.
If there are any omissions, please correct me!
On April 15, NMPA's official website showed that Jiangsu Hengrui Medicine's medium and long-chain fatty emulsion/amino acid (16)/glucose (16%) injection was approved (Guoyao Zhunzi H20223219); on the same day, the company announced that gadolinium The abbreviated new drug application (ANDA) for meglumine acid injection has been approved
.
.
Figure 1: Sales of medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection is an "all-in-one" parenteral nutrition injection, used for mild to moderate when oral or enteral nutrition cannot be performed, insufficient or contraindicated.
Patients with severe catabolism provide energy, essential fatty acids, amino acids, electrolytes, and fluids for parenteral nutrition therapy
.
Patients with severe catabolism provide energy, essential fatty acids, amino acids, electrolytes, and fluids for parenteral nutrition therapy
.
At present, in addition to the original research and imported drugs in the domestic market, Kelun and Hisco obtained the production approval in 2018, and subsequently passed the consistency evaluation.
This product is the third domestic enterprise
.
This product is the third domestic enterprise
.
According to data from Minet.
com, domestic brands have boosted the sales of products after their listing.
In 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, medium and long-chain fat emulsion / The sales growth rate of amino acid (16)/glucose (16%) injection is as high as 238.
64%, and there is also a 172% increase in the first half of 2021
.
From the perspective of the corporate structure, domestic brands have jointly grabbed the market leadership, and the market share of original research pharmaceutical companies will be less than 1% in the first half of 2021
.
com, domestic brands have boosted the sales of products after their listing.
In 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, medium and long-chain fat emulsion / The sales growth rate of amino acid (16)/glucose (16%) injection is as high as 238.
64%, and there is also a 172% increase in the first half of 2021
.
From the perspective of the corporate structure, domestic brands have jointly grabbed the market leadership, and the market share of original research pharmaceutical companies will be less than 1% in the first half of 2021
.
Table 1: The ANDA number that Hengrui has obtained
Source: Minet Global Listed Drug Database
On April 15, Jiangsu Hengrui Pharmaceutical announced that the company's abbreviated new drug application (ANDA) for gadoteric acid meglumine injection submitted to the US FDA was approved, which means that the product can be produced and sold in the US market
.
.
It is reported that gadoteric acid meglumine injection is a gadolinium-based intravenous contrast agent for MRI of the brain (intracranial), spine and related tissues in adults and children (including neonates) to check for blood-brain barrier damage and Vascular abnormalities
.
In the first half of 2021, Hengrui's gadoteric acid meglumine injection ranked twelfth among the TOP20 brands of terminal contrast media in China's public medical institutions
.
.
In the first half of 2021, Hengrui's gadoteric acid meglumine injection ranked twelfth among the TOP20 brands of terminal contrast media in China's public medical institutions
.
In recent years, Hengrui has been actively deploying preparations to go overseas.
So far, nearly 20 ANDA approvals have been obtained, most of which are injections
.
So far, nearly 20 ANDA approvals have been obtained, most of which are injections
.
Source: NMPA official website, Minet database
Note: The statistics of the global marketed drug database of Minet.
com are as of April 6.
If there are any omissions, please correct me!
com are as of April 6.
If there are any omissions, please correct me!
On April 15, NMPA's official website showed that Jiangsu Hengrui Medicine's medium and long-chain fatty emulsion/amino acid (16)/glucose (16%) injection was approved (Guoyao Zhunzi H20223219); on the same day, the company announced that gadolinium The abbreviated new drug application (ANDA) for meglumine acid injection has been approved
.
.
Figure 1: Sales of medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection is an "all-in-one" parenteral nutrition injection, used for mild to moderate when oral or enteral nutrition cannot be performed, insufficient or contraindicated.
Patients with severe catabolism provide energy, essential fatty acids, amino acids, electrolytes, and fluids for parenteral nutrition therapy
.
Patients with severe catabolism provide energy, essential fatty acids, amino acids, electrolytes, and fluids for parenteral nutrition therapy
.
At present, in addition to the original research and imported drugs in the domestic market, Kelun and Hisco obtained the production approval in 2018, and subsequently passed the consistency evaluation.
This product is the third domestic enterprise
.
enterprise enterprise enterpriseThis product is the third domestic enterprise
.
According to data from Minet.
com, domestic brands have boosted the sales of products after their listing.
In 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, medium and long-chain fat emulsion / The sales growth rate of amino acid (16)/glucose (16%) injection is as high as 238.
64%, and there is also a 172% increase in the first half of 2021
.
From the perspective of the corporate structure, domestic brands have jointly grabbed the market leadership, and the market share of original research pharmaceutical companies will be less than 1% in the first half of 2021
.
hospital hospital hospitalcom, domestic brands have boosted the sales of products after their listing.
In 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, medium and long-chain fat emulsion / The sales growth rate of amino acid (16)/glucose (16%) injection is as high as 238.
64%, and there is also a 172% increase in the first half of 2021
.
From the perspective of the corporate structure, domestic brands have jointly grabbed the market leadership, and the market share of original research pharmaceutical companies will be less than 1% in the first half of 2021
.
Table 1: The ANDA number that Hengrui has obtained
Source: Minet Global Listed Drug Database
On April 15, Jiangsu Hengrui Pharmaceutical announced that the company's abbreviated new drug application (ANDA) for gadoteric acid meglumine injection submitted to the US FDA was approved, which means that the product can be produced and sold in the US market
.
medicine medicine medicine.
It is reported that gadoteric acid meglumine injection is a gadolinium-based intravenous contrast agent for MRI of the brain (intracranial), spine and related tissues in adults and children (including neonates) to check for blood-brain barrier damage and Vascular abnormalities
.
In the first half of 2021, Hengrui's gadoteric acid meglumine injection ranked twelfth among the TOP20 brands of terminal contrast media in China's public medical institutions
.
children children children.
In the first half of 2021, Hengrui's gadoteric acid meglumine injection ranked twelfth among the TOP20 brands of terminal contrast media in China's public medical institutions
.
In recent years, Hengrui has been actively deploying preparations to go overseas.
So far, nearly 20 ANDA approvals have been obtained, most of which are injections
.
So far, nearly 20 ANDA approvals have been obtained, most of which are injections
.
Source: NMPA official website, Minet database
Note: The statistics of the global marketed drug database of Minet.
com are as of April 6.
If there are any omissions, please correct me!
com are as of April 6.
If there are any omissions, please correct me!
